Scholarlink

<p>Type 1 Diabetes (T1D) is characterized by the destruction of insulin-producing β cells, leading to hyperglycemia. New therapeutic strategies are crucial for preventing or managing the disease and its complications. Natural or recombinant probiotics, by modulating the gut microbiota and dictating the immunological tolerance, have been recently employed as tolerogenic immunotherapy for autoimmune diseases. Heat shock protein 65 (HSP65) exhibits regulatory and anti-inflammatory activity in autoimmune and chronic inflammatory conditions. Here, we show that dendritic cells from T1D patients exhibit reduced expression of immunological tolerance-associated genes and diminished TLR2 expression. Recombinant HSP65 (rHSP65) upregulated <i>Tlr2</i> expression and promoted the differentiation of classical dendritic cell subsets—cDC1 and cDC2—capable of inducing regulatory T cells (Tregs) in vitro. Mice administered <i>L. lactis</i>-HSP65 became resistant to T1D, proved by reduced hyperglycemia and lower disease incidence compared to diabetic group that did not receive probiotic. These mice exhibited increased TLR2<sup>+</sup> cDC1 and PD-1<sup>+</sup> Treg cells in the cecum-associated mesenteric lymph node. Furthermore, <i>L. lactis</i>-rHSP65 increased Treg population, IL-10, and TGF-β production in the pancreas. In TLR2-deficient mice, the tolerogenic effects of <i>L. lactis</i>-HSP65 were not observed. TLR2 and IL-10-deficient DCs cannot drive the Treg differentiation in vitro. Overall, the results indicate that <i>L. lactis</i>-HSP65 protects against T1D onset by immunoregulatory effects mediated by tolerogenic cDC1 through a mechanism involving TLR2 and IL-10.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactococcus lactis-HSP65 requires TLR2 to induce tolerogenic dendritic cells and confer protection against type 1 diabetes in a murine model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月2日

查看全文
  • Jefferson Elias-Oliveira,
  • Vanessa Fernandes Rodrigues,
  • Ítalo Sousa Pereira,
  • Sara Cândida Barbosa,
  • Jéssica Assis Pereira,
  • Thaílla Cristina Faria Pacheco,
  • Melissa Santana Gonsalez Machado,
  • Ana Paula Masson,
  • Wendy Martin Rios,
  • Luiz Gustavo Gardinassi,
  • Anderson Miyoshi,
  • Vasco Azevedo,
  • Célio Lopes Silva,
  • Rita Cássia Tostes,
  • Daniela Carlos

摘要

Type 1 Diabetes (T1D) is characterized by the destruction of insulin-producing β cells, leading to hyperglycemia. New therapeutic strategies are crucial for preventing or managing the disease and its complications. Natural or recombinant probiotics, by modulating the gut microbiota and dictating the immunological tolerance, have been recently employed as tolerogenic immunotherapy for autoimmune diseases. Heat shock protein 65 (HSP65) exhibits regulatory and anti-inflammatory activity in autoimmune and chronic inflammatory conditions. Here, we show that dendritic cells from T1D patients exhibit reduced expression of immunological tolerance-associated genes and diminished TLR2 expression. Recombinant HSP65 (rHSP65) upregulated Tlr2 expression and promoted the differentiation of classical dendritic cell subsets—cDC1 and cDC2—capable of inducing regulatory T cells (Tregs) in vitro. Mice administered L. lactis-HSP65 became resistant to T1D, proved by reduced hyperglycemia and lower disease incidence compared to diabetic group that did not receive probiotic. These mice exhibited increased TLR2+ cDC1 and PD-1+ Treg cells in the cecum-associated mesenteric lymph node. Furthermore, L. lactis-rHSP65 increased Treg population, IL-10, and TGF-β production in the pancreas. In TLR2-deficient mice, the tolerogenic effects of L. lactis-HSP65 were not observed. TLR2 and IL-10-deficient DCs cannot drive the Treg differentiation in vitro. Overall, the results indicate that L. lactis-HSP65 protects against T1D onset by immunoregulatory effects mediated by tolerogenic cDC1 through a mechanism involving TLR2 and IL-10.

Graphical Abstract